ANI reports record Q4 net rev $227.8mln, up 53.6% YoY.

• ANI reports Q3 net revenues of $227.8mln, up 53.6% YoY. • Purified Cortrophin Gel revenue increases 93.8% YoY to $101.9mln. • Q3 adjusted EBITDA reaches $59.6mln, up 69.8% YoY. • Diluted GAAP income per share is $1.13, with adjusted EPS at $2.04. • ANI raises 2025 net revenue guidance to $854-$873mln, EBITDA to $221-$228mln, and EPS to $7.37-$7.64.